Skip to main content
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care
  • Subscribe
  • Log in
  • My Cart
  • Follow ada on Twitter
  • RSS
  • Visit ada on Facebook
Diabetes

Advanced Search

Main menu

  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
  • More from ADA
    • Diabetes Care
    • Clinical Diabetes
    • Diabetes Spectrum
    • ADA Standards of Medical Care in Diabetes
    • ADA Scientific Sessions Abstracts
    • BMJ Open Diabetes Research & Care

User menu

  • Subscribe
  • Log in
  • My Cart

Search

  • Advanced search
Diabetes
  • Home
  • Current
    • Current Issue
    • Online Ahead of Print
    • ADA Scientific Sessions Abstracts
  • Browse
    • By Topic
    • Issue Archive
    • Saved Searches
    • ADA Scientific Sessions Abstracts
    • Diabetes COVID-19 Article Collection
    • Diabetes Symposium 2020
  • Info
    • About the Journal
    • About the Editors
    • ADA Journal Policies
    • Instructions for Authors
    • Guidance for Reviewers
  • Reprints/Reuse
  • Advertising
  • Subscriptions
    • Individual Subscriptions
    • Institutional Subscriptions and Site Licenses
    • Access Institutional Usage Reports
    • Purchase Single Issues
  • Alerts
    • E­mail Alerts
    • RSS Feeds
  • Podcasts
    • Diabetes Core Update
    • Special Podcast Series: Therapeutic Inertia
    • Special Podcast Series: Influenza Podcasts
    • Special Podcast Series: SGLT2 Inhibitors
    • Special Podcast Series: COVID-19
  • Submit
    • Submit a Manuscript
    • Submit Cover Art
    • ADA Journal Policies
    • Instructions for Authors
    • ADA Peer Review
Oral Presentations

Improvements in A1C and Time-in-Range in DIY Closed-Loop (OpenAPS) Users

  1. DANA M. LEWIS,
  2. RICHARD S. SWAIN and
  3. THOMAS W. DONNER
  1. Seattle, WA, College Park, MD, Baltimore, MD
Diabetes 2018 Jul; 67(Supplement 1): -. https://doi.org/10.2337/db18-352-OR
Previous
  • Article
  • Figures & Tables
  • Info & Metrics
Loading

Abstract

Overview: We performed a retrospective study that analyzed outcomes from a subset (n=20) of the Do It Yourself (DIY) closed loop community. This already well-controlled, highly motivated T1D population realized further improvements in A1c and glucose time in range (TIR), and a reduction in time spent high and low during all timeframes after beginning a DIY hybrid closed loop “artificial pancreas” system.

Objective: To compare mean BG, TIR (70-180 mg/dl), and time above and below clinically meaningful thresholds before and after OpenAPS initiation.

Methods: We performed a retrospective cross-over analysis of continuous BG readings recorded during 2-week segments 4-6 weeks before and after initiation of OpenAPS (Johns Hopkins IRB00121066). Mean BG and TIR were analyzed overall, as well as by day (7am-11pm) and night (11pm-7am), and statistical significance was assessed using paired t-tests.

Results: Mean BG and TIR improved in every time category. Overall, mean BG (mg/dl) improved (135.7 to 128.3); as did mean estimated HbA1c (6.4 to 6.1%). TIR increased from 75.8 to 82.2% overall. Overnight, BG time <70 was reduced from 6.4 to 4.2%, and time <50 was reduced from 2.3 to 1.0%. Overall, BG excursions >300 were reduced from 1.7 to 0.35%.

Conclusion: Even with tight initial control, persons with T1D saw meaningful improvements in estimated A1c, TIR, and a reduction in time spent high and low, during the day and at night, after initiating OpenAPS.

Figure1
  • Download figure
  • Open in new tab
  • Download powerpoint

Disclosure D.M. Lewis: Consultant; Self; Tandem Diabetes Care, Inc.. R.S. Swain: None. T.W. Donner: Research Support; Self; Novo Nordisk Inc., Viacyte, Inc..

  • © 2018 by the American Diabetes Association.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

Previous
Back to top
Diabetes: 67 (Supplement 1)

In this Issue

July 2018, 67(Supplement 1)
  • Table of Contents
  • Index by Author
  • Abstract PDFs
Sign up to receive current issue alerts
View Selected Citations (0)
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about Diabetes.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Improvements in A1C and Time-in-Range in DIY Closed-Loop (OpenAPS) Users
(Your Name) has forwarded a page to you from Diabetes
(Your Name) thought you would like to see this page from the Diabetes web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Improvements in A1C and Time-in-Range in DIY Closed-Loop (OpenAPS) Users
DANA M. LEWIS, RICHARD S. SWAIN, THOMAS W. DONNER
Diabetes Jul 2018, 67 (Supplement 1) 352-OR; DOI: 10.2337/db18-352-OR

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Add to Selected Citations
Share

Improvements in A1C and Time-in-Range in DIY Closed-Loop (OpenAPS) Users
DANA M. LEWIS, RICHARD S. SWAIN, THOMAS W. DONNER
Diabetes Jul 2018, 67 (Supplement 1) 352-OR; DOI: 10.2337/db18-352-OR
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Figures & Tables
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

Oral Presentations

  • The Role of Exosomes in Improvement of Insulin Sensitivity in Obese Adolescents following Bariatric Surgery
  • Serum Uric Acid (SUA), Urinary Albumin Excretion (UAE), and Hypertension (HTN) in Adolescents with Type 2 Diabetes (T2D) in the TODAY Study
  • Hybrid Insulin Peptides Form in Islets of Nondiabetes Prone Mice
Show more Oral Presentations

Clinical Diabetes/Therapeutics

  • Predictors of Preferences for Use of MK-1293 Pens among Patients with Diabetes—Findings from a Multinational Study in the U.S., Canada, and U.K.
  • Diabetes Management in Hospitalized Patients with Type 2 Diabetes (T2D) during Fasting Periods
  • The Impact of Endocrinology Consultation in the United States on Global Diabetes Care
Show more Clinical Diabetes/Therapeutics

Clinical Therapeutics/New Technology–Insulin Delivery Systems

  • A Reusable Cap for Disposable Insulin Pens Protects Insulin against Temperature-Induced Degradation
  • Long-Term Use of Omnipod® Insulin Management System Associated with Lower A1c in Adults with Established Diabetes and A1c =8%
  • Predictors of Preferences for Use of MK-1293 Pens among Patients with Diabetes—Findings from a Multinational Study in the U.S., Canada, and U.K.
Show more Clinical Therapeutics/New Technology–Insulin Delivery Systems

Similar Articles

Navigate

  • Current Issue
  • Online Ahead of Print
  • Scientific Sessions Abstracts
  • Collections
  • Archives
  • Submit
  • Subscribe
  • Email Alerts
  • RSS Feeds

More Information

  • About the Journal
  • Instructions for Authors
  • Journal Policies
  • Reprints and Permissions
  • Advertising
  • Privacy Policy: ADA Journals
  • Copyright Notice/Public Access Policy
  • Contact Us

Other ADA Resources

  • Diabetes Care
  • Clinical Diabetes
  • Diabetes Spectrum
  • Scientific Sessions Abstracts
  • Standards of Medical Care in Diabetes
  • BMJ Open - Diabetes Research & Care
  • Professional Books
  • Diabetes Forecast

 

  • DiabetesJournals.org
  • Diabetes Core Update
  • ADA's DiabetesPro
  • ADA Member Directory
  • Diabetes.org

© 2021 by the American Diabetes Association. Diabetes Print ISSN: 0012-1797, Online ISSN: 1939-327X.